Himal Amin

2.8k total citations · 1 hit paper
13 papers, 1.4k citations indexed

About

Himal Amin is a scholar working on Hematology, Molecular Biology and Oncology. According to data from OpenAlex, Himal Amin has authored 13 papers receiving a total of 1.4k indexed citations (citations by other indexed papers that have themselves been cited), including 12 papers in Hematology, 6 papers in Molecular Biology and 6 papers in Oncology. Recurrent topics in Himal Amin's work include Multiple Myeloma Research and Treatments (12 papers), Chronic Lymphocytic Leukemia Research (5 papers) and Monoclonal and Polyclonal Antibodies Research (4 papers). Himal Amin is often cited by papers focused on Multiple Myeloma Research and Treatments (12 papers), Chronic Lymphocytic Leukemia Research (5 papers) and Monoclonal and Polyclonal Antibodies Research (4 papers). Himal Amin collaborates with scholars based in United States, Netherlands and Australia. Himal Amin's co-authors include Xiang Qin, Jordan M. Schecter, Pieter Sonneveld, María‐Victoria Mateos, Ajay K. Nooka, Vânia Hungria, Andrew Spencer, Katja Weisel, Ming Qi and William Deraedt and has published in prestigious journals such as New England Journal of Medicine, Journal of Clinical Oncology and Blood.

In The Last Decade

Himal Amin

13 papers receiving 1.4k citations

Hit Papers

Daratumumab, Bortezomib, and Dexamethasone for Multiple M... 2016 2026 2019 2022 2016 250 500 750 1000
What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

  1. Daratumumab, Bortezomib, and Dexamethasone for Multiple Myeloma
    2016 1.1k citations Antonio Palumbo, Asher Chanan‐Khan et al. New England Journal of Medicine profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Himal Amin United States 8 1.1k 870 685 197 166 13 1.4k
Kevin Yee United States 9 499 0.5× 480 0.6× 303 0.4× 267 1.4× 65 0.4× 12 1.2k
Anuj Mahindra United States 17 918 0.9× 703 0.8× 477 0.7× 227 1.2× 47 0.3× 56 1.2k
Matthew Jenner United Kingdom 23 1.4k 1.3× 1.3k 1.5× 755 1.1× 200 1.0× 82 0.5× 86 1.8k
Brea Lipe United States 16 504 0.5× 471 0.5× 299 0.4× 97 0.5× 57 0.3× 76 901
Carmen Chillón Spain 25 793 0.7× 715 0.8× 387 0.6× 354 1.8× 23 0.1× 76 1.5k
Michal Bar‐Natan United States 15 719 0.7× 524 0.6× 312 0.5× 364 1.8× 70 0.4× 41 1.3k
Angela Gernone Italy 9 273 0.3× 342 0.4× 265 0.4× 69 0.4× 122 0.7× 32 782
Pamela L. Clemens United States 15 557 0.5× 329 0.4× 468 0.7× 134 0.7× 15 0.1× 33 803
Gordon Moody United States 11 135 0.1× 281 0.3× 303 0.4× 90 0.5× 38 0.2× 24 836
Weili Sun United States 12 253 0.2× 296 0.3× 164 0.2× 83 0.4× 25 0.2× 29 891

Countries citing papers authored by Himal Amin

Since Specialization
Citations

This map shows the geographic impact of Himal Amin's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Himal Amin with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Himal Amin more than expected).

Fields of papers citing papers by Himal Amin

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Himal Amin. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Himal Amin. The network helps show where Himal Amin may publish in the future.

Co-authorship network of co-authors of Himal Amin

This figure shows the co-authorship network connecting the top 25 collaborators of Himal Amin. A scholar is included among the top collaborators of Himal Amin based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Himal Amin. Himal Amin is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

13 of 13 papers shown
1.
Dosne, Anne‐Gaëlle, Xia Li, Man Luo, et al.. (2022). Population pharmacokinetics and exposure–response analyses of daratumumab plus pomalidomide/dexamethasone in relapsed or refractory multiple myeloma. British Journal of Clinical Pharmacology. 89(5). 1640–1655. 3 indexed citations
2.
Terpos, Evangelos, Meletios Α. Dimopoulos, Mario Boccadoro, et al.. (2021). Health-related quality of life (HRQoL) in patients with relapsed/refractory multiple myeloma (RRMM) treated with pomalidamide and dexamethasone ± subcutaneous daratumumab: Patient-reported outcomes (PROs) in APOLLO.. Journal of Clinical Oncology. 39(15_suppl). 8046–8046. 1 indexed citations
3.
Mateos, María‐Victoria, Pieter Sonneveld, Vânia Hungria, et al.. (2019). Daratumumab, Bortezomib, and Dexamethasone Versus Bortezomib and Dexamethasone in Patients With Previously Treated Multiple Myeloma: Three-year Follow-up of CASTOR. Clinical Lymphoma Myeloma & Leukemia. 20(8). 509–518. 93 indexed citations
4.
Mateos, María‐Victoria, Pieter Sonneveld, Vânia Hungria, et al.. (2018). Efficacy and Safety of Daratumumab, Bortezomib, and Dexamethasone (D-Vd) Versus Bortezomib and Dexamethasone (Vd) in First Relapse Patients: Two-Year Update of Castor. Blood. 132(Supplement 1). 3270–3270. 8 indexed citations
5.
6.
Lentzsch, Suzanne, Katja Weisel, María‐Victoria Mateos, et al.. (2017). Daratumumab, bortezomib and dexamethasone (DVd) vs bortezomib and dexamethasone (Vd) in relapsed or refractory multiple myeloma (RRMM): Efficacy and safety update (CASTOR).. Journal of Clinical Oncology. 35(15_suppl). 8036–8036. 8 indexed citations
7.
Palumbo, Antonio, Asher Chanan‐Khan, Katja Weisel, et al.. (2016). Daratumumab, Bortezomib, and Dexamethasone for Multiple Myeloma. New England Journal of Medicine. 375(8). 754–766. 1056 indexed citations breakdown →
8.
Mateos, María‐Victoria, Jane Estell, Wolney Barreto, et al.. (2016). Efficacy of Daratumumab, Bortezomib, and Dexamethasone Versus Bortezomib and Dexamethasone in Relapsed or Refractory Myeloma Based on Prior Lines of Therapy: Updated Analysis of Castor. Blood. 128(22). 1150–1150. 28 indexed citations
9.
Palumbo, Antonio, Asher Chanan‐Khan, Katja Weisel, et al.. (2016). Phase III randomized controlled study of daratumumab, bortezomib, and dexamethasone (DVd) versus bortezomib and dexamethasone (Vd) in patients (pts) with relapsed or refractory multiple myeloma (RRMM): CASTOR study.. Journal of Clinical Oncology. 34(15_suppl). LBA4–LBA4. 2 indexed citations
10.
Palumbo, Antonio, Asher Chanan‐Khan, Katja Weisel, et al.. (2016). Phase III randomized controlled study of daratumumab, bortezomib, and dexamethasone (DVd) versus bortezomib and dexamethasone (Vd) in patients (pts) with relapsed or refractory multiple myeloma (RRMM): CASTOR study.. Journal of Clinical Oncology. 34(18_suppl). LBA4–LBA4. 19 indexed citations
11.
12.
13.
Meininger, Gary, Russell Scott, Maria Alba, et al.. (2011). Effects of MK-0941, a Novel Glucokinase Activator, on Glycemic Control in Insulin-Treated Patients With Type 2 Diabetes. Diabetes Care. 34(12). 2560–2566. 158 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Kevin Yee Breakdown of academic impact, for papers by Anuj Mahindra Breakdown of academic impact, for papers by Matthew Jenner Breakdown of academic impact, for papers by Brea Lipe Breakdown of academic impact, for papers by Carmen Chillón Breakdown of academic impact, for papers by Michal Bar‐Natan Breakdown of academic impact, for papers by Angela Gernone Breakdown of academic impact, for papers by Pamela L. Clemens Breakdown of academic impact, for papers by Gordon Moody Breakdown of academic impact, for papers by Weili Sun
Rankless by CCL
2026